**Amendments to the Claim:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1 (Currently Amended). A compound comprising two individual peptide sequences, wherein at least one of the two individual peptide sequences comprises an amino acid sequence of the formula (I)

L1-A-L2-B-L3-C-L4-D-L5

wherein

one of A, B, C, D is selected from a hydrophobic amino acid residue,

one of A, B, C, D is selected from a basic amino acid residue, Asn or Gln,

one of A, B, C, D is selected from an acidic amino acid residue, Asn or Gln,

one of A, B, C, D is Gly or Ala, and

L1, L2, L3, L4 and L5 is selected from a chemical bond or an amino acid sequence having n amino acid residues, wherein n is an integer of from 0 to 5,

wherein

said peptide sequences are connected to each other through a linker of the formula (II)

X[(A)nCOOH][(B)mCOOH]

n and m independently are an integer of from 1 to 20,

X is HN, $H_2N(CR_2)pCR$, $RHN(CR_2)pCR$, $HO(CR_2)pCR$, $HS(CR_2)pCR$, halogen-$(CR_2)pCR$, $HOOC(CR_2)pCR$, $ROOC(CR_2)pCR$, $HCO(CR_2)pCR$, $RCO(CR_2)pCR$, $[HOOC(A)n][HOOC(B)m]CR(CR_2)pCR$, $H_2N(CR_2)p$, $RHN(CR_2)p$, $HO(CR_2)p$, $HS(CR_2)p$, halogen-$(CR_2)p$, $HOOC(CR_2)p$, $ROOC(CR_2)p$, $HCO(CR_2)p$, $RCO(CR_2)p$, or $[HOOC(A)n][HOOC(B)m](CR_2)p$, wherein p is 0 or integer of from 1 to 20,

A and B independently are a substituted or unsubstituted $C_{1-10}$ alkyl, a substituted or unsubstituted $C_{2-10}$ alkenyl, a substituted or unsubstituted cyclic moiety, a substituted or unsubstituted heterocyclic moiety, a substituted or unsubstituted aromatic moiety, or A and B together form a substituted or unsubstituted cyclic moiety, substituted or unsubstituted heterocyclic moiety, or substituted or unsubstituted aromatic moiety

wherein said peptide sequence of formula (I) and said compound are capable of binding to a receptor selected from the family of fibroblast growth factor receptors (FGFRs) consisting of FGFR1, FGFR2, FGFR3, and FGFR4.

2-3 (Cancelled).

4 (Currently Amended). The compound according to claim ~~2~~ 1, wherein the at least one of the two peptide sequences is derived from the sequence of a polypeptide selected from the group consisting of cell adhesion molecules, cell-surface receptors, heparan sulphate proteoglycans, and metalloproteases, extracellular matrix molecules or growth factors.

5 (Previously Presented). The compound according to claim 4, wherein the cell adhesion molecule is selected from the group consisting of
Neural Cell Adhesion Molecule (NCAM) (Swiss-Prot Ass. Nos: P13591,
P13595-01, P13595),
Neural cell adhesion molecule L1 (Swiss-Prot Ass. Nos: Q9QYQ7, Q9QY38,
P11627, Q05695, P32004),
Neural Cell Adhesion Molecule-2 (NCAM-2) (Swiss-Prot Ass. No: P36335)

Neuron-glia Cell Adhesion Molecule (Ng-CAM) (Swiss-Prot Ass. No: Q03696;
Q90933),
Neural cell adhesion molecule CALL (Swiss-Prot Ass. No: O00533),
Neuroglian (Swiss-Prot Ass. No: P91767, P20241),
Nr-CAM (HBRAVO, NRCAM, NR-CAM 12) (Swiss-Prot Ass. Nos: Q92823,
O15179, Q9QVN3
Axonin-1/TAG-1 (Swiss-Prot Ass. Nos: Q02246, P22063, P28685 ),
Axonal-associated Cell Adhesion Molecule (AxCAM) (NCBI Ass. No:
NP_031544.1; Swiss-Prot Ass. No: Q8TC35),
Myelin-Associated Glycoprotein (MAG) (Swiss-Prot Ass. No: P20917),
Neural cell adhesion molecule BIG-1 (Swiss-Prot Ass. No: Q62682),
Neural cell adhesion molecule BIG-2 (Swiss-Prot Ass. No: Q62845),
Fasciclin (FAS-2) (Swiss-Prot Ass. No: P22648),
Neural cell adhesion molecule HNB-3/NB-3 (Swiss-Prot Ass. Nos: Q9UQ52,
P97528, Q9JMB8)
Neural cell adhesion molecule HNB-2/NB-2 (Swiss-Prot Ass. Nos: O94779,
P07409, P97527),
Cadherin (Swiss-Prot Ass. No: Q9VW71),
Junctional Adhesion Molecule-1 (JAM-1) (Swiss-Prot Ass. Nos: Q9JKD5,
O88792),
Neural cell adhesion F3/F11(Contactin) (Swiss-Prot Ass. Nos: Q63198, P1260,
Q12860, Q28106, P14781, O93250),
Neurofascin (Swiss-Prot Ass. Nos: Q90924, Q91Z60; O42414),
B-lymphocyte cell adhesion molecule CD22 (Swiss-Prot Ass. Nos:

Q9R094,
P20273),
Neogenin (NEO1) (Swiss-Prot Ass. Nos: Q92859, P97603, Q90610, P97798),
Intercellular Cell Adhesion Molecule-5 (ICAM-5/telencephalin) (Swiss-Prot Ass.
Nos: Q8TAM9, Q60625) or
Galactose binding lectin-12 (galectin-12) (Swiss-Prot Ass. Nos: Q91VD1,
Q9JKX2, Q9NZ03) and
Galactose binding lectin-4 (galectin-4) (Swiss-Prot Ass. No: Q8K419; P38552).

6 (Previously Presented). The compound according to claim 4, wherein the cell-surface receptor is selected from the group consisting of
Fibroblast Growth Factor Receptor 1 (FGFR1) (Swiss-Prot Ass. Nos: Q9QZM7,
Q99AVV7, Q9UD50, Q63827),
Fibroblast Growth Factor Receptor 2 (FGFR2) (Swiss-Prot Ass. Nos: Q96KM2,
P21802, Q63241),
Fibroblast Growth Factor Receptor 3 (FGFR3) (Swiss-Prot Ass. Nos: Q95M13,
AF487554, Q99052),
Fibroblast Growth Factor Receptor 4 (FGFR4) (Swiss-Prot Ass. No: Q91742),
Neurotrophin Tyrosin Kinase Type-2 (NTRKT-2) (Swiss-Prot Ass. No:
Q8WXJ5),
Leukocyte Antigen Related Protein-Tyrosine Phosphatase (LAR-PTPRF)
(Swiss-Prot Ass. Nos: Q9EQ17, Q64605, Q64604, Q9QW67, Q9VIS8 P10586),
Nephrin (Swiss-Prot Ass. Nos: Q925S5, Q9JIX2, Q9ET59, Q9R044,

Q9QZS7,
Q06500),
Protein-Tyrosine Phosphatase Receptor type S (PTPRS)
(Swiss-Prot Ass.
Nos: Q64699, Q13332, O75870),
Protein-Tyrosine Phosphatase Receptor type kappa (R-PTP-kappa)
(Swiss-
Prot Ass. No: Q15262),
Protein-Tyrosine Phosphatase Receptor type D (PTPRD)
(Swiss-Prot Ass.
Nos: Q8WX65, Q9IAJ1, P23468, Q64487),
Ephrin type-A receptor 8 (EPHA8/Tyrosine-Protein Kinase
Receptor EEK)
(Swiss-Prot Ass. Nos: O09127, P29322),
Ephrin type-A receptor 3 (EPHA8/Tyrosine-Protein Kinase
Receptor ETK-
1/CEK4) (Swiss-Prot Ass. No: P29318),
Ephrin type-A receptor 2 (Swiss-Prot Ass. No: Q8N3Z2)
Insulin Receptor (IR) (Swiss-Prot Ass. No: Q9PWN6)
Insulin-like Growth Factor-1 Receptor (IGF-1) (Swiss-Prot Ass.
Nos: Q9QVW4,
P08069, P24062, Q60751, P15127, P15208)
Insulin-related Receptor (IRR) (Swiss-Prot Ass. No: P14616),
-Tyrosine-Protein Kinase Receptor Tie-1 (Swiss-Prot Ass. Nos:
06805,
P35590, Q06806),
Roundabout receptor-1 (robo-1) (Swiss-Prot Ass. Nos: O44924,
AF041082,
Q9Y6N7),
Neuronal nicotinic acetylcholine receptor alpha 3 subunit
(CHRNA3) (Swiss-
Prot Ass. Nos: Q8VHH6, P04757, Q8R4G9, P32297)
Neuronal acetylcholine receptor alpha 6 subunit (Swiss-Prot
Ass. Nos:
Q15825, Q9R0W9)

Platelet-Derived Growth Factor Receptor Beta (PDGFRB) (Swiss-Prot Ass.
Nos: Q8R406, Q05030),
Interleukin-6 Receptor (IL-6R) (Swiss-Prot Ass. No: Q00560),
Interleukin-23 Receptor (IL-23R) (Swiss-Prot Ass. No: AF461422),
Beta-common cytokine receptor of IL-3, IL5 and GmCsf (Swiss-Prot Ass. No:
P32927)
Cytokine Receptor-Like molecule 3 (CRLF1) (Swiss-Prot Ass. No: Q9JM58),
Class I Cytokine Receptor (ZCYTOR5) (Swiss-Prot Ass. No: Q9UHH5)
Netrin-1 receptor DCC (Swiss-Prot Ass. No: P43146),
Leukocyte Fc Receptor-like Protein (IFGP2) (Swiss-Prot Ass. Nos: Q96PJ6,
Q96KM2),
Macrophage Scavenger Receptor 2 (MSR2) (Swiss-Prot Ass. No: Q91YK7) and
Granulocyte Colony Stimulating Factor Receptor ( G-CSF-R) (Swiss-Prot Ass.
No: Q99062).

7 (Withdrawn). The compound according to claim 4, wherein the heparan sulphate proteoglycan is perlecan (Swiss-Prot Ass. No: P98160).

8 (Withdrawn). The compound according to claim 4, wherein the metalloprotease is selected from the group consisting of
ADAM-8 (Swiss-Prot Ass. No: Q05910),
ADAM-19 (Swiss-Prot Ass. Nos: Q9H013, O35674),
ADAM-8 (Swiss-Prot Ass. No: P78325),
ADAM-12 (Swiss-Prot Ass. Nos: O43184, Q61824),
ADAM-28 (Swiss-Prot Ass. Nos: Q9JLN6, Q61824, Q9XSL6, Q9UKQ2),
ADAM-33 precursor (Swiss-Prot Ass. Nos: Q8R533, Q923W9),

ADAM-9 (Swiss-Prot Ass. Nos: Q13433, Q61072),
ADAM-7 (Swiss-Prot Ass. NoS: Q9H2U9, O35227, Q63180),
ADAM-1A Fertilin alpha (Swiss-Prot Ass. No: Q8R533),
ADAM-15 (Swiss-Prot Ass. Nos: Q9QYV0, O88839, Q13444),
Metalloproteinase-desintegrin domain containing protein (TECAM) (Swiss-Prot
Ass. No: AF163291), and
Metalloproteinase 1 (Swiss-Prot Ass. Nos: O95204, Q9BSI6).

9 (Withdrawn). The compound according to claim 4, wherein the extracellular matrix molecule is selected from the group consisting of
Collagen type VII (Swiss-Prot Ass. No: Q63870),
Fibronectin (Swiss-Prot Ass. Nos: Q95KV4, Q95KV5, P07589, Q28377,
U42594, O95609, P11276), and
Tenascin-R (Swiss-Prot Ass. Nos: Q15568, O00531, Q90995, P10039).

10 (Withdrawn). The compound according to claim 4, wherein the growth factor is Cytokine-like factor-1 (CLF-1)
(Swiss-Prot Ass. No:O75462).

11 (Currently Amended). The compound according to claim 1, wherein the at least one of the two peptide sequences ~~is a peptide fragment having the~~ consists of an amino acid sequence selected from the group consisting of
EVYVVAENQQGKSKA (SEQ ID NO 1),
NIEVWVEAENALGKKV (SEQ ID NO: 2),
ATNRQGKVKAFAHL (SEQ ID NO: 3),
RYVELYVVADSQEFQK (SEQ ID NO: 4)
VAENSRGKNVAKG (SEQ ID NO: 5),
GEYWCVAENQYGQR (SEQ ID NO: 6),
RLAALNGKGLGEIS (SEQ ID NO: 7),
KYIAENMKAQNVAKEI (SEQ ID NO: 8),

~~TIMGLKPETRYAVR (SEQ ID NO: 9),~~
~~KGLGEISAATEFKT (SEQ ID NO: 10),~~
~~NMGIWVQAENALG (SEQ ID NO: 11),~~
~~IWVQAENMLG (SEQ ID NO: 12),~~
EIWVEATNRLG (SEQ ID NO: 13),
~~VWVQAANALG (SEQ ID NO: 14),~~
EVWIEKDPAKGRI (SEQ ID NO: 15),
ATNKGGEVKKNGHL (SEQ ID NO: 16),
KYVELYLVADYLEFQK (SEQ ID NO: 17),
RYVELYVVVDNAEFQ (SEQ ID NO: 18),
KYVELVIVADNREFQR (SEQ ID NO: 19),
KYIEYYLVLDNGEFKR (SEQ ID NO: 20),
RYLELYIVADHTLF (SEQ ID NO: 21),
~~KYVEMFVVVNHQRFQ (SEQ ID NO: 22),~~
~~RYVELFIVVDKERY (SEQ ID NO: 23),~~
KYVELFIVADDTVYRR (SEQ ID NO: 24),
KFIELFVVADEYVYRR (SEQ ID NO: 25),
KIVEKVIVADNSEVRK (SEQ ID NO: 26),
VELVIVADHSEAQK (SEQ ID NO: 27),
VAENSRGKNIAKG (SEQ ID NO: 28),
IAENSRGKNVARG (SEQ ID NO: 29),
AENSRGKNSFRG (SEQ ID NO: 30),
IASNLRGRNLAKG (SEQ ID NO: 31),
IPENSLGKTYAKG (SEQ ID NO: 32),
IAENMKAQNEAK (SEQ ID NO: 33),
QFIAENMKSHNETKEV (SEQ ID NO: 34),
GEYWCVAKNRVGQ (SEQ ID NO: 35),
GSYTCVAENMVGK (SEQ ID NO: 36),
GKYVCVGTNMVGER (SEQ ID NO: 37),
~~GNYTCVVENEYG (SEQ ID NO: 38),~~
~~GEYTCLAGNSIG (SEQ ID NO: 39),~~
~~QYYCVAENGYG (SEQ ID NO: 40),~~
~~GEYYQEAEQNGYG (SEQ ID NO: 41),~~
~~GNYTCLVENEYG (SEQ ID NO: 42),~~
~~GMYQCLAENAYG (SEQ ID NO: 43),~~

~~GMYQCAENTHG (SEQ ID NO: 44),~~
~~GIYYCLASNNYG (SEQ ID NO: 45),~~
~~GGYYCTADNSYG (SEQ ID NO: 46),~~
GEYQCFARNDYG (SEQ ID NO: 47),
GEYFCLASNKMG (SEQ ID NO: 48),
GEYQCFARNKFG (SEQ ID NO: 49),
GEYFCLASNKMG (SEQ ID NO: 50),
~~GGYYCTADNNYG (SEQ ID NO: 51),~~
GNYSCEAENAWGTK (SEQ ID NO: 52),
~~GEYTCLAENSLG (SEQ ID NO: 53),~~
GEYECVAENGRLG (SEQ ID NO: 54),
GNYTCVVENKFGR (SEQ ID NO: 55),
~~GEYTCLAGNSIG (SEQ ID NO: 56),~~
~~GEYFCVASNPIG (SEQ ID NO: 57),~~
~~EYTCIANNQAGE (SEQ ID NO: 58),~~
GMYQCVAENKHLG (SEQ ID NO: 59),
~~GEYMCTASNTIGQ (SEQ ID NO: 60),~~
~~EYVCIAENKAGEQ (SEQ ID NO: 61),~~
GDYTLIAKNEYGK (SEQ ID NO: 62),
~~GFYQCVAENEAG (SEQ ID NO: 63),~~
GKYECVATNSAGTR (SEQ ID NO: 64),
~~GEYFCVYNNSLG (SEQ ID NO: 65),~~
GEYECAATNAHGR (SEQ ID NO: 66),
GAYWCQGTNSVGK (SEQ ID NO: 67),
~~GTYSCVAENILG (SEQ ID NO: 68),~~
RVAAVNGKGQGDYS (SEQ ID NO: 69),
RVAAINGCGIGPFS (SEQ ID NO: 70),
AVLNGKGLG (SEQ ID NO: 71),
~~ALNGQGLGATS (SEQ ID NO: 72),~~
RLAAKNRAGLGE (SEQ ID NO: 73),
~~RLGVVTGKDLGEI (SEQ ID NO: 74),~~
~~TVTGLKPETSYMVK (SEQ ID NO: 75),~~
~~TLTGLKPSTRYRI (SEQ ID NO: 76),~~
~~TLTGLQPSTRYRV (SEQ ID NO: 77),~~
~~TLLGLKPDTTYDIK (SEQ ID NO: 78),~~

~~TLQGLRPETAYELR (SEQ ID NO: 79),~~
~~TLRGLRPETAYELR (SEQ ID NO: 80),~~
~~TLMNLRPKTGYSVR (SEQ ID NO: 81),~~
~~TVSGLKPGTRY (SEQ ID NO: 82),~~
~~TISGLKPDTTY (SEQ ID NO: 83),~~
~~TLQGLKPDTAY (SEQ ID NO: 84),~~
~~LRGLKPWTQYAV (SEQ ID NO: 85),~~
~~IDGLEPDTEYIVR (SEQ ID NO: 86),~~
~~LQGLKPWTQYAI (SEQ ID NO: 87),~~
~~TITGLEPGTEYTIQ (SEQ ID NO: 88),~~
~~GLKPWTQYAV (SEQ ID NO: 89),~~
~~TLASLKPWTQYAV (SEQ ID NO: 90),~~
~~LMGLQPATEYIV (SEQ ID NO: 91),~~
~~KGMGPMSEAVQFRT (SEQ ID NO: 92),~~
~~TLTGLKPDTTYDVK (SEQ ID NO: 93),~~
~~ISGLQPETSYSL (SEQ ID NO: 94),~~
~~TLLGLKPDTTYDIK (SEQ ID NO: 95),~~
~~TISGLTPETTYSI (SEQ ID NO: 96),~~
GNYSCLAENRLGR (SEQ ID NO: 97),
~~GNYTCVVENRVG (SEQ ID NO: 98),~~
GTYHCVATNAHG (SEQ ID NO: 99),
~~LSHNGVLTGYLLSY (SEQ ID NO: 100),~~
~~NGVLTGYVLRY (SEQ ID NO: 101),~~
~~NGVLTGYNLRY (SEQ ID NO: 102),~~
~~NGNLTGYLLQY (SEQ ID NO: 103),~~
~~VDENGVLTGYKIYY (SEQ ID NO: 104),~~
~~THNGALVGYSVRY (SEQ ID NO: 105),~~
~~NGILTEYILKY (SEQ ID NO: 106),~~
~~NGILIGYTLRY (SEQ ID NO: 107),~~
~~THSGQITGYKIRY (SEQ ID NO: 108),~~
~~NGKITGYIIYY (SEQ ID NO: 109),~~
~~LSHNGIFTLY (SEQ ID NO: 110),~~
~~NGILTEYTLKY (SEQ ID NO: 111),~~
~~LDPNGIITQYEISY (SEQ ID NO: 112),~~
~~NGKITGYIIYY (SEQ ID NO: 113),~~

HLEVQAFNGRGSGPA (SEQ ID NO: 114),
HLTVRAYNGAGYGP (SEQ ID NO: 115),
HLSVKAYNSAGTGPS (SEQ ID NO: 116),
HLAVKAYNSAGTGPS (SEQ ID NO: 117),
NLEVRAFNSAGDGP (SEQ ID NO: 118),
HLTVLAYNSKGAGP (SEQ ID NO: 119),
LRVLVFNGRGDGP (SEQ ID NO: 120),
HIDVSAFNSAGYGP (SEQ ID NO: 121),
HLAVELFNGR (SEQ ID NO: 122),
LELQSINFLGGQPA (SEQ ID NO: 123),
HFTVRAYNGAGYGP (SEQ ID NO: 124),
HLEVQAFNGRGSQPA (SEQ ID NO: 125),
~~VIADQPTFVKYLIK (SEQ ID NO: 126),~~
~~TIKGLRPGVVYEGQ (SEQ ID NO: 127),~~
~~TLTELSPSTQYTVK (SEQ ID NO: 128),~~
~~TLDDLAPDTTYLVQ (SEQ ID NO: 129),~~
~~TVSDVTPHAIYTVR (SEQ ID NO: 130),~~
~~IIRGLNASTRYLFR (SEQ ID NO:131),~~
~~TLMNLRPKTGYSVR (SEQ ID NO:132),~~
~~TLTGLKPGTEYEVR (SEQ ID NO: 133),~~
~~GPEHLMPSSTYVAR (SEQ ID NO: 134),~~
~~RVTGLTPKKTYEFR (SEQ ID NO: 135),~~
~~LTGLKPGTEYEFR (SEQ ID NO: 136),~~
EVRVQAVNGGGNGPP (SEQ ID NO: 137),
LIKVVAINDRGE (SEQ ID NO: 138),
VVSIIAVNGREE (SEQ ID NO: 139),
VVSVYAQNQNGE (SEQ ID NO: 140),
TISLVAEKGRHK (SEQ ID NO: 141),
HLEVQAFNGRGSGPA (SEQ ID NO: 142),
HVEVQAFNGRGLGPA (SEQ ID NO: 143),
HVEVQAFNGRGLGPA (SEQ ID NO: 144), and
EFRVRAVNGAGEG (SEQ ID NO: 145)~~, and~~
~~VARVRTRLAPGSRLS (SEQ ID NO: 146),~~
~~or a fragment, or a variant, or homologue thereof,~~
~~wherein~~

~~said fragment is an amino acid sequence which has at least 40% of the length of a sequence selected from the group consisting of SEQ ID NOs:1-146 and which is capable of binding to fibroblast growth factor receptor,~~
~~said variant is an amino acid sequence which has at least 60% of homology to a sequence selected from the group consisting of SEQ ID NOs: 1-146 and which is capable of binding to fibroblast growth factor receptor, and~~
~~said homologue is an amino acid sequence which has at least 20% homology to a sequence selected from the group consisting of SEQ ID NOs: 1-146 and which is capable of binding to fibroblast growth factor receptor~~.

12 (Currently Amended). The compound according to claim 1, wherein the at least one of the two peptide sequences is SEQ ID NO: 1 (EVYVVAENQQGKSKA)~~, or a fragment, variant, or homologue of said sequence~~.

13 (Cancelled).

14 (Currently Amended). The compound according to claim 1, wherein the at least one of the two peptide sequences is SEQ ID NO: 2 (NIEVWVEAENALGKKV)~~, or a fragment, variant or homologue of said sequence~~.

15 (Currently Amended). The compound according to claim 1, wherein the compound comprises two individual peptide fragments, each comprising a different amino acid sequence~~s~~, said different amino acid sequences being selected independently from said group of amino acid sequences.

16 (Currently Amended). The compound according to claim 1, wherein the compound comprises two peptide fragments each comprising ~~the~~ an identical amino acid sequence, said identical amino acid sequence being selected from said group

of amino acid sequences.

17 (Currently Amended). The compound according to claim 16, wherein the peptide fragments ~~have~~ consist of the sequence EVYVVAENQQGKSKA (SEQ ID NO: 1).

18 (Currently Amended). The compound according to claim 16, wherein the peptide fragments ~~have~~ consist of the sequence NIEVWVEAENALGKKV (SEQ ID NO: 2).

19 (Currently Amended). The compound according to claim 15, wherein one of the two peptide fragments ~~has~~ consists of the sequence EVYVVAENQQGKSKA (SEQ ID NO: 1), and the other ~~has~~ consists of the sequence NIEVWVEAENALGKKV (SEQ ID NO: 2).

20 (Currently Amended). The compound according to claim 11, said compound being obtained by a method comprising the steps of
providing by solid phase synthesis or fragment coupling ligands comprising desired sequence(s), the ligands being attached to a solid phase,
if nessesary, deprotecting any N-terminal amino acid groups while ~~th eligands/s)~~ the ligand(s) are still attached to the solid phase, reacting the ligand(s) having unprotected N-terminal groups with an achiral di- tri- or tetracarboxylic acid so as to provide a construct having a ring structure, and cleaving the construct from the solid phase so as to provide an LPA comprising ligands having free C-terminal groups.

21 (Previously Presented). A pharmaceutical composition comprising a compound as defined in claim 1.

22 (Withdrawn - Currently Amended). Method of treatment comprising administering an effective amount of a compound as defined in claim 1 for treatment of conditions of the central

and peripheral nervous system associated with postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic damage, [[,]] Parkinson's disease, Alzheimer's disease, Huntington's disease, dementias, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia, mood disorders; for treatment of diseases or conditions of the muscles; or for treatment of diseases or conditions of the gonads, pancreas, kidney, heart, liver or bowel.

23 (Withdrawn - Currently Amended). Method of treatment comprising administering an effective amount of a compound as defined in claim 1 for the treatment of postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic damage, [[,]] Parkinson's disease, Alzheimer's disease, Huntington's disease, dementias, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, schizophrenia, or mood disorders.

24 (Withdrawn). Method of treatment comprising administering an effective amount of a compound as defined in claim 1 for the promotion of wound-healing.

25 (Withdrawn). Method of treatment comprising administering an effective amount of a compound as defined in claim 1 for the treatment of cancer.

26 (Withdrawn). The method of treatment according to claim 25, wherein the cancer is any type of solid tumor requiring neoangiogenesis.

27 (Withdrawn - Currently Amended). Method of treatment comprising administering an effective amount of a compound as

defined in claim 1 for the prevention of death of heart muscle cells[[,]].

28 (Withdrawn). Method of treatment comprising administering an effective amount of a compound as defined in claim 1 for revascularization.

29 (Withdrawn). Method of treatment comprising administering an effective amount of a compound as defined in claim 1 for the stimulation of the ability to learn and/or the short and/or long-term memory.

30 (Withdrawn). Method of treatment comprising administering an effective amount of a compound as defined in claim 1 for the prevention of cell death due to ischemia.

31 (Withdrawn). Method of treatment comprising administering an effective amount of a compound as defined in claim 1 for the prevention of body damage due to alcohol consumption.

32 (Withdrawn). Method of treatment comprising administering an effective amount of a compound as defined in claim 1 for the treatment of prion diseases.

33-34 (Cancelled).

35 (New). The compound according to claim 16, wherein the peptide fragments each comprise the sequence EVYVVAENQQGKSKA (SEQ ID NO: 1).

36 (New). The compound according to claim 16, wherein the peptide fragments each comprise the sequence NIEVWVEAENALGKKV (SEQ ID NO: 2).

37 (New). The compound according to claim 15, wherein one of

the two peptide fragments comprises the sequence EVYVVAENQQGKSKA (SEQ ID NO: 1), and the other comprises the sequence NIEVWVEAENALGKKV (SEQ ID NO: 2).

38 (New). The compound of claim 1 wherein both peptide sequences, which may be the same or different, satisfy formula (I).

39 (New). The compound of claim 1 wherein the at least one peptide sequence comprises at least 9 consecutive amino acids of SEQ ID NO:1 or SEQ ID NO:2.

40 (New). The compound of claim 1 wherein at least one peptide sequence comprises a sequence having at least 50% positive amino acid matches with SEQ ID NO:1.

41 (New). The compound of claim 1 wherein at least one peptide sequence comprises a sequence having at least 60% positive amino acid matches with SEQ ID NO:1.

42 (New). The compound of claim 1 wherein at least one peptide sequence comprises a sequence having at least 90% positive amino acid matches with SEQ ID NO:1.

43 (New). The compound of claim 1 wherein at least one peptide sequence consists of a sequence selected from the group consisting of SEQ ID NOs:1-8.

44 (New). The compound of claim 1 which comprises a sequence at least 90% identical to SEQ ID NO:1.

45 (New). The compound of claim 1 wherein at least one of said individual peptide sequences comprises the sequence

$X_1$-$X_2$-$X_3$-$X_4$-$X_5$-$X_6$-$X_7$-$X_8$

wherein $X_1$ through $X_8$ are amino acids;

at least one of $X_1$ and $X_6$ is hydrophobic;
at least one of $X_2$, $X_5$ and $X_7$ is Gly or Ala;
at least one of $X_3$, $X_4$, $X_5$, and $X_6$ is acidic, Asn or Gln; and
$X_8$ is basic.

46 (New). The compound of claim 1 wherein at least one of said individual peptide sequences comprises the sequence (D/E/N/Q)-3 amino acids-(R/K/H).

47 (New). The compound of claim 46 wherein at least one of said individual peptide sequences comprises the sequence N-3 amino acids-K.

48 (New). The compound of claim 1 wherein at least one of said individual peptide sequences comprises the sequence (A/G)-(D/E/N/Q)-(D/E/N/Q)-(2 amino acids)-(A/G)-(R/K/H).

49 (New). The compound of claim 1 wherein at least one of said individual peptide sequences comprises the sequence AEN-2 amino acids-GK (SEQ ID NO:147).